focus -WSS

focus

author：entertainment 2025-09-03 11:20:53 - browse：7331

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Long Covid needs a new name — and a new frame

WSS

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Will the IRA bring competition to the biologics market?

A common UTI test for kids haunts adults as a traumatic 'nightmare'

hotspot

focus

focus

Walensky prepares to leave CDC — and Congress — behind

Doctors increasingly discourage vaping amid mounting health concerns

How one medical school became remarkably diverse

What AstraZeneca

Apple is now the first public company to be valued at $3 trillion

Private equity could exacerbate cardiology's overuse problem, experts fear

Wildfire smoke exposes gaps in outdoor worker protections

Regeneron agrees to White House price limits on anti

Guidelines to prevent youth baseball injuries need more muscle

House GOP plan to stem drug shortages differs from Democrats’

focus

5 wounded, 2 critically, in Michigan shopping center shooting

Telehealth for opioid use disorder is lifesaving

Judge orders hearing on Trump's motion to disqualify Fulton County DA

HCA says smaller share of spending going to labor

White House touts steps to stem shortages of cancer treatments

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

focus

leisure time

hotspot

explore